Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of TAK-875 compared to placebo on
glycemic control over a 24-week Treatment Period when used as an add-on to glimepiride in
addition to diet and exercise.